fda semaglutide warning US warns online vendors to stop selling unapproved weight-loss drugs FDA clears GLP-1 weight loss

NAION and Semaglutide: New Research Findings Recent studies have shed light on a potential link between semaglutide use and an increased risk of Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

Peptides may enhance physical therapy outcomes by accelerating tissue adaptation to therapeutic exercise and reducing pain that limits participation

TW has received travel support from Novartis and Sanofi and research funding from Novartis and AstraZeneca

Vyvanse is a central nervous system stimulant used to treat ADHD and BED

Survodutide (BI 456906) is similar to the active ingredient tirzepatide (Mounjaro, Zepbound) in that it combines two mechanisms of action